Is ARYx Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, ARYx Therapeutics Inc (ARYX) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is ARYx Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ARYx Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of ARYx Therapeutics Inc?

Muslim investors may consider investing in ARYx Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is ARYx Therapeutics Inc classified as NOT COVERED?

Musaffa determines the Shariah status of ARYx Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for ARYx Therapeutics Inc updated?

The Shariah compliance status of ARYx Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like ARYx Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of ARYx Therapeutics Inc?

You can check the latest Shariah compliance status of ARYx Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ARYx Therapeutics Inc. Stock Analysis ARYX

United States Health Care Nano Cap

ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. The company is headquartered in Fremont, California and currently employs 56 full-time employees. The company went IPO on 2007-11-08. The firm is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. The company is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

Financial Metrics & Statements of ARYx Therapeutics Inc (ARYX)

FAQ's for ARYx Therapeutics Inc (ARYX)

According to Musaffa’s Shariah screening methodology, ARYx Therapeutics Inc (ARYX) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.